We have developed a highly specific and robust new method for labeling adeno-associated virus (AAV) vector particles with either biophysical probes or targeting ligands. Our approach uses the Escherichia coli enzyme biotin ligase (BirA), which ligates biotin to a 15-aminoacid biotin acceptor peptide (BAP) in a sequence-specific manner. In this study we demonstrate that by using a ketone isotere of biotin as a cofactor we can ligate this probe to BAP-modified AAV capsids. Because ketones are absent from AAV, BAP-modified AAV particles can be tagged with the ketone probe and then specifically conjugated to hydrazide-or hydroxylamine-functionalized molecules. We demonstrate this two-stage modification methodology in the context of a mammalian cell lysate for the labeling of AAV vector particles with various fluorophores, and for the attachment of a synthetic cyclic arginine-glycine-aspartate (RGD) peptide (c(RGDfC)) to target integrin receptors that are present on neovasculature. Fluorophore labeling allowed the straightforward determination of intracellular particle distribution. Ligand conjugation mediated a significant increase in the transduction of endothelial cells in vitro, and permitted the intravascular targeting of AAV vectors to tumorassociated vasculature in vivo. These results suggest that this approach holds significant promise for future studies aimed at understanding and modifying AAV vectorcellular interactions.
IntroductIon
Biophysical probes such as fluorophores have been very useful for investigating the process of adeno-associated virus (AAV) infection, [1] [2] [3] [4] [5] but technological hurdles have limited their use, and their chemical conjugation to viral particles is often associated with a significant loss of titer. Green fluorescent protein (GFP) is an attractive option because of its high-labeling specificity and ease of use, but it is a large tag (238 amino acids) and can be used only for fluorescent imaging. While GFP has been fused to the aminoterminus of AAV2 VP2, and particles incorporating this fusion have been generated, 6, 7 it is unclear whether this approach will be universally adaptable to the other AAV serotypes, and the influence of such a large tag on AAV biology has yet to be thoroughly evaluated. Furthermore, the low valency of VP2 display significantly lessens the signal intensity obtained using this approach. Other protein-based tags that either react covalently or form high affinity complexes with small-molecule probes have yet to be introduced into AAV particles, but the problem of size remains. 8, 9 Labeling approaches that use peptides rather than proteins as targeting sequences are less invasive but generally sacrifice specificity and efficiency. For instance, the FlAsH technology, which targets arsenic-functionalized fluorophores to tetracysteine motifs displayed on recombinant proteins, requires complex washout procedures to remove the probe from nontarget monothiols, and the labeling is unstable. 10 Fluorophore-binding peptide aptamers similarly show reduced specificity as compared to protein tag-based methods 11 and, while a recently developed hexahistidine-based labeling approach may offer higher specificity, it also relies on a noncovalent interaction that deteriorates within minutes. 12 In recent years, there have been intensive efforts in many laboratories to generate targeted AAV vectors by modifying the cellbinding characteristics of these particles. The primary strategy has been to genetically modify the AAV capsid proteins, [13] [14] [15] [16] [17] [18] while an alternative strategy has been to use soluble bifunctional crosslinkers that bind both to the vector particle and to a cell-surface receptor, thereby providing a molecular bridge to anchor the vector to a targeted receptor. 19 A combined approach has been the display of an immunoglobulin binding domain on the vector as a genetic fusion to the capsid protein, and then the use of a monoclonal antibody to crosslink the vector with the targeted cell. 20 While the genetic insertion of targeting peptide motifs into the AAV capsid has met with the greatest success, this approach is often problematic, and does not lend itself to the high-throughput evaluation of different targeting ligands. Often, the genetic insertion dramatically reduces vector titer or DNA packaging Furthermore, some peptide epitopes are inefficiently or inappropriately displayed when engineered into AAV capsids, or are rendered unable to bind their targeted receptor in the context of AAV virions, 17 further reducing the effectiveness of this approach. To date, all AAV vector-targeting strategies have been based on the assumption that an engineered interaction between the vector and a cell-surface receptor will result in more efficient gene delivery by promoting enhanced attachment or altering intracellular trafficking pathways. However, given the myriad different entry mechanisms employed by naturally occurring viruses, it is not surprising that this simple assumption has not always proven correct. Although the engineered interactions mediated by capsid modification have invariably proven necessary for enhanced transduction, the mechanisms by which vector modification can increase transduction have been shown to vary, and have required a detailed intracellular analysis for their full characterization (M.D.S. and J.S.B., unpublished observation). Therefore, a single technology that allows vector modification with both targeting ligands and biophysical probes to monitor intracellular events would be of great benefit to the field. Ideally such a technology should permit straightforward incorporation of targeting ligands into the AAV vector system, allow their rapid evaluation without the need for genetic manipulation, and combine the minimal invasiveness of a small peptide tag with the excellent labeling specificity of GFP for intracellular particle localization. Moreover, the modification strategy should be covalent, so that probe or ligand dissociation is not a concern. In order to address this problem, we capitalized on the Escherichia coli enzyme BirA, which catalyzes the biotinylation of a lysine side-chain within a 15-amino acid consensus "biotin acceptor peptide" (BAP) sequence. BirA has already been used for the specific biotinylation of BAP-modified AAV vectors. 21 The mechanism of biotinylation involves activation of biotin as an adenylate ester, followed by its trapping by the lysine side-chain of the BAP. In order to harness the specificity of BirA for ligation of other biophysical probes or targeting ligands to BAP-modified AAV particles, we utilized ketone 1, a biotin isostere with the ureido nitrogens replaced by methylene groups (Figure 1a) . Ketone 1 also serves as a substrate for BirA. 22 Because the ketone group is absent from natural proteins, carbohydrates, and lipids, it can be selectively derivatized on the vector surface with hydrazide-or hydroxylamine-bearing compounds under physiological conditions. 23 In this study we describe the development of a new site-specific vector modification methodology (Figure 1 ) based on the ability of BirA to use ketone 1 efficiently in place of biotin. We show that this approach permits the ligation of either targeting ligands or biophysical probes to vector particles, and demonstrate the usefulness of the technology for both AAV vector-targeting and intracellular particle-trafficking studies. results site-specific labeling of AAV particles with biophysical probes In order to test the use of BirA and ketone 1 for the labeling of recombinant AAV vectors, we generated BAP-modified AAV by genetically inserting the BAP into the coding sequence of the AAV1 capsid proteins. 21 Partially purified BAP-modified AAV1 was first enzymatically labeled with ketone 1 using BirA, and then Alexa Fluor hydrazides were added to derivatize the ketones. The resulting product was either used directly, or reduced with sodium cyanoborohydride to improve its stability, and separated from excess fluorophore by gel filtration. Fluorophore-labeled AAV particles produced in this manner could be readily detected within infected cells by fluorescence microscopy (Figure 2) . Ketone modification required adenosine triphosphate, thereby showing that conjugation was dependent on enzyme activity and on the presence of the BAP in the viral particle and further indicating that the labeling was site-specific (Figure 2b and c) . Specificity was further assessed by competing cellular binding of fluorophore-labeled AAV1 particles with wheat germ agglutinin, a specific inhibitor of AAV1 cellular attachment (Figure 2d ). Using this approach, the sensitivity was found to be significantly greater than that of previous fluorescent labeling methodologies, 1, 2 and allowed the determination of intracellular particle distribution at much lower multiplicities of infection than had been previously possible 1, 2 (Figure 2e ). Because the coupling was performed enzymatically, the reaction conditions are quite gentle and perhaps more appropriate for the modification of complex biomolecules such as viruses. In fact, there was no loss of vector titer after either ketone modification or fluorophore conjugation ( Figure 3) . In order to ensure that labeling would not affect alternative receptor usage, AAV1-based vectors engineered to infect human endothelial cells through alternative receptors (Tie2, the cell-surface receptor for angiopoietin; or integrin) were also labeled with fluorophores using this approach. In each case the enhanced transduction properties of these vectors was maintained after probe conjugation (Figure 3) .
In order to explore the utility of BirA-catalyzed AAV particle modification, we examined the intracellular distribution of tropism-modified AAV vectors as compared to unmodified AAV vectors by labeling particles with different fluorophores. AAV1 vector particles comprised of AAVCap1.D590_P591insBAP capsid proteins, and integrin-targeted mosaic AAV1 vector particles comprised of both AAVCap1.D590_P591insBAP and AAVCap1. D590_P591insRGD capsid proteins (1:4 ratio) were individually enzymatically labeled with ketone 1, and then derivatized with Alexa Fluor hydrazide 555 or Alexa Fluor hydrazide 488, respectively. The functionalized particles were then added together to cultured human endothelial cells and the particle distribution was assessed at 60 minutes after infection using fluorescence microscopy. This approach allowed multiple wavelength imaging and the straightforward determination of different intracellular localizations exhibited by tropism-modified vectors as compared to unmodified vectors (Figure 4) . Importantly, the labeling reactions could be carried out with only small amounts of vector and did not require extensive vector purification either pre-or postlabeling, thereby overcoming the two significant drawbacks to current labeling technologies.
1,2 Furthermore, because of its size in comparison to GFP, the 15-amino-acid BAP tag is less likely to alter the trafficking of AAV particles. We have shown earlier that the BAP tag does not alter vector-mediated gene transduction or in vivo tropism. 21 Therefore this labeling approach seems to be minimally invasive and should allow the introduction of a wide range of probes with which to study AAV distribution and function in live cells.
Addition of targeting ligands to AAV vector particles with biotin ligase
The targeting of gene delivery to tumors is a central challenge for improving existing cancer gene therapies, because it is likely to enhance the efficacy and decrease the side-effects of these approaches. While various strategies have been pursued to achieve this goal, the most commonly used vehicles for targeting nongene-based therapies to tumors are "engineered antibodies," i.e., bispecific antibodies or antibody fragments. 24, 25 The incorporation of these agents into gene delivery systems has been problematic and has led to only limited success, especially with AAV-based vectors. "Homing" peptides are promising alternatives, because they bind to surface molecules that are specific to organ or tumor cells, 26, 27 are smaller than the antibody fragments, and can be genetically incorporated into AAV capsid proteins. 14, 16, 17 A prominent example of a homing peptide is the arginine-glycine-aspartate (RGD) motif. 26, 28 This motif is present in many extracellular matrix components such as fibronectin and vitronectin, and binds to integrins. RGD-analogs have been extensively used for tumor imaging, 29 in antiangiogenesis approaches, 30, 31 and in tumor targeting with radionucleotides 31 or chemotherapeutic drugs. 27 We have shown earlier that AAV1-and AAV2-based vectors that display genetically incorporated RGD motifs mediate significantly better gene transfer to endothelial cells and tumor cells than unmodified vectors do, 17, 32, 33 and that RGD-modified AAV1 vectors can effectively target gene delivery to tumor-associated vasculature when administered intravenously to tumor-bearing animals (M.D.S. and J.S.B., unpublished observation).
Here we assessed the use of BirA and ketone 1 for conjugation of a synthetic cyclic RGD peptide (c(RGDfC)) to the surface of BAP-modified recombinant AAV1 vectors. Partially purified BAP-modified AAV1dsRed2 particles (AAV1.D590_ P591insBAP capsid proteins) were first enzymatically labeled with ketone 1 (Figure 1 ) and then derivatized with cRGD peptide that had been modified with EMCH to create a free hydrazide. The cRGD-modified AAV1dsRed2 vector demonstrated significantly enhanced transduction efficacy in cultured human endothelial cells as compared to unmodified AAV1dsRed2 vector ( Figure 5 ). Enhanced transduction was specific for the targeted integrin receptor, because it could be effectively competed using an anti-integrin antibody ( Figure 5) . Importantly, the cRGD-modified AAV1eGFP vector was able to mediate efficient gene transfer to tumor-associated vasculature in a murine model of peritoneal ovarian cancer after intravascular administration (Figure 6) . These data clearly demonstrate that BirA and ketone 1 have the potential to add synthetic-targeting ligands to AAV particles for modifying vector tropism. 
dIscussIon
We have developed a new methodology for tagging AAV vectors with biophysical probes using a 15-amino-acid BAP sequence and the enzyme BirA. The method is highly specific because it capitalizes on the sequence-specificity of BirA, and it is versatile because the ketone platform allows the introduction of a wide range of probes.
BirA-based labeling is superior to existing labeling approaches that are based on conjugation of small-molecule fluorophores. Conventional succinimidyl ester forms of common dyes such as fluorescein isothiocyanate, carbocyanine dyes, and the Alexa dyes, react with amines on the capsid surface; this means that they are selective for lysine side chains, as well as for the N-termini of the capsid protein monomers. Reactivity of the amines requires that they be deprotonated, so these reactions are typically carried out at pH values between 8.3 and 9.3, 2,5 depending upon the stability of the dye. While the variations in pH may be attributable to historical precedent, as opposed to careful optimization, it is clear that AAV does not tolerate these conditions for extended periods of time. Therefore, conjugation of small-molecule fluorophores to AAV is often associated with loss of titer, particle aggregation, or low-labeling efficiency. Because BirA-based labeling is enzymatic and carried out at a more neutral pH, it is considerably more gentle and efficient than the amine-reactive chemistries used earlier. Furthermore, BirA-based labeling is site-specific, allowing far greater control over probe conjugation and minimizing the effects on viral biology.
To our knowledge this method is the only reported example of enzyme-mediated site-specific modification of a viral particle. A unique advantage of this method is that the ketone platform allows the introduction of a wide variety of different probes or targeting ligands. Earlier, targeting ligands incorporated into AAV vectors were limited to either small peptides [13] [14] [15] [16] [17] [18] or antibodies. 19, 20 Our method should provide a considerably more robust platform for the incorporation of not only peptide and protein ligands, but also of natural lectins, carbohydrates, glycolipids, polymers, and synthetic ligands into AAV particles. Similarly, although we show data only for the conjugation of fluorescent probes to AAV particles, modification of vectors with other biophysical probes should also be possible. Such probes could be used to monitor properties such as vesicular pH, capsid disassembly, or phospolipase activity.
In conclusion, we have developed a new AAV-labeling and modification methodology that combines the specificity of GFP tagging with the minimal invasiveness of a small peptide. We have demonstrated the labeling of AAV particles with fluorophores and the use of this approach to study vector trafficking in live cells. We have also shown that this method could be used to specifically attach targeting ligands to AAV vector particles, and that vectors modified in this manner could mediate enhanced gene transfer to target cells both in vitro and in vivo. Future efforts will focus on extending this methodology to additional biophysical probes for studying AAV vector entry and intracellular processing, and to different targeting ligands for targeted gene delivery.
MAterIAls And MetHods
Recombinant AAV production. Low passage number (passage number 20-40) HEK 293 cells 34 and HeLa C12 cells 35 were grown in Dulbecco's modified Eagle's medium supplemented with 10% cosmic calf serum (Hyclone, Logan, UT), penicillin (100 U/ml), and streptomycin (100 U/ml) at 37 °C and 5% CO 2 . Plasmid pXR1-Cap1.D590_P591insBAP, 21 pXR1-Cap1.D590_P591insRGD, 33 or pXR1 (ref. 36 ) DNA was triple transfected with the previously described pXX6-80 (containing the adenovirus VA, E2A, and E4 genes) 37 and either pTR-UF5 (containing the enhanced GFP (eGFP) gene driven by the cytomegalovirus enhancer/promoter in a standard AAV plasmid vector) or pTrsSKcmvRFP (containing the dsRed2 fluorescent protein gene driven by the cytomegalovirus enhancer/promoter and in a self-complementary AAV plasmid vector) into HEK 293 cells. 33 A 1:1:1 molar ratio of plasmids was used. For generating mosaic AAV1 virions containing the two different modified capsid proteins, the different helper constructs were mixed at 1:4 molar ratio before transfection. However, the total amount of helper plasmid used for vector production remained constant. Transfections were carried out at 37 °C using the calcium phosphate transfection system (Invitrogen, Carlsbad, CA) in accordance with the manufacturer's specifications. Sixty hours after transfection, the cells were harvested by centrifugation at 500 g for 10 minutes and resuspended in 100 mmol/l NaCitrate, 2.5 mmol/l MgCl 2 , 10 mmol/l Tris pH 8.3. The vector was then released by three cycles of freeze-thaw. The crude lysate was clarified by centrifugation at 500 g for 10 minutes, viscosity was reduced by the addition of Benzonase (50 U/ml) and incubation at 37 °C for 30 minutes, and the lysate was then fractionated on an iodixanol step gradient as previously described. 38 DNase-resistant particle (DRP) values were determined using real-time PCR assay and infectious titers were determined by gene transduction assay on HeLa C12 cells, as described previously. 16, 39 Probe ligation and hydrazide conjugation. Racemic ketone 1 was synthesized and attached to BAP-modified AAV vector particles as described earlier for ligation to synthetic peptides and BAP-modified cyan fluorescent protein (CFP). 22 Briefly, iodixanol purified BAP-modified AAV1 was added to an equal volume of bicine buffer (50 mmol/l bicine, 5 mmol/l magnesium acetate, pH 8.3) containing 8 mmol/l adenosine triphosphate, 200 μmol/l racemic ketone 1, and 2 μmol/l BirA. Reactions were incubated at 30 °C for 3 hours, and 0.1 mol/l HCl was added to adjust the pH to 6.5-7. For fluorescent labeling, Alexa Fluor 488 hydrazide or Alexa Fluor 555 hydrazide (Invitrogen) was added to a final concentration of 500 μmol/l, and the reaction was incubated at 30 °C for 8-18 hours. Excess unreacted hydrazide was removed by gel filtration (HiTrap; Amersham Biosciences, Piscataway, NJ). Cyclic-RGD peptide (c(RGDfC)); Peptides International, Louisville, KY) was modified with EMCH (3,3ʹ-N-[e-Maleimidocaproic acid] hydrazide, trifluoroacetic acid salt; Pierce) in accordance with the manufacturers recommendations, creating a hydrazide that was then conjugated to a ketonemodified vector overnight at 30 °C. For the most part, reaction mixtures containing modified AAV vectors were used without subsequent treatment or purification. However, in some instances, sodium cyanoborohydride (15 mmol/l) was added to reduce the hydrazone, for 1.5 hours at 4 °C.
22
Intracellular particle distribution studies. Human HeLa C12 cells or umbilical vein endothelial cells were grown on chambered microscope slides in Dulbecco's modified Eagle's medium (Hyclone) supplemented with 10% fetal bovine serum or complete EBM-2 media (Clonetics, Walkersville, MD) respectively at 37 °C in a 5% CO 2 atmosphere. Nonspecific binding was blocked by incubating the cells for 30 minutes at 4 °C with serumfree and supplement-free medium containing 5% bovine serum albumin and image-iT FX reagent (Invitrogen). Fluorophore-conjugated AAV (5 × 10 4 -1 × 10 6 DRP/cell) was added to the blocking solution and left on the cells for 1 hour at 4 °C. Where indicated, wheat germ agglutinin (10 mg/ml; Vector Laboratories, Burlingame, CA) was added at the same time as the virus. The cells were then washed three times with phosphate-buffered saline and fresh growth medium was added. The cells were incubated at 37 °C in a 5% CO 2 atmosphere for 15 minutes. Noninternalized particles were removed with an acid wash (50 mmol/l 2-(N-morpholino)ethanesulonic acid, 280 mmol/l sucrose, pH 5.0) 2 and either fixed immediately with 4% paraformaldahyde for 15 minutes, or returned to 37 °C for 60 minutes prior to fixing. Slides were mounted using Vectashield mounting medium (Vector Laboratories) and images were collected using an Olympus BX61 microscope and Hamamatsu ORCA-ER digital camera controlled by Slidebook v4.0 software (Intelligent Imaging Innovations, Denver, CO). When indicated, image stacks were deconvolved using a constrained iterative algorithm in Slidebook v4.0. Merged images of "x-y" planes through the middle of cells are presented.
Gene transduction assays. For analysis of enhanced gene transduction mediated by vector modification, human umbilical vein endothelial cells were seeded onto 48-well plates and treated with vector preparations (3 × 10 4 DRP/cell) at ~80% confluency. The cells were maintained at 37 °C for 16 hours and washed three times with phosphate-buffered saline before fresh growth media was added. For the determination of ligand-dependent enhancement of gene transduction, vectors were added to target cells for 2 hours at 4 °C in the presence of an anti-integrin monoclonal antibody (LM609), or an isotype-matched control antibody. The cells were then washed three times with fresh medium to remove unbound vector and returned to 37 °C. Gene transduction was determined 90 hours after treatment by counting red fluorescent protein-positive cells using an inverted fluorescent microscope (10 fields of view/well). All transduction assays were performed in triplicate, and the results are presented as mean values ± SD. Statistical analysis was performed using GraphPad Prism version 4.0b for Macintosh (GraphPad Software). Analysis was performed using Student's t-test for comparison of two groups. Results were considered significant when P < 0.05.
Ovarian carcinoma model and immunostaining for targeted gene delivery. Tumors were established by injecting 2 × 10 6 DsRed2-expressing SKOV-3 cells intraperitoneally into female athymic nude (nu/nu) mice. Two weeks later, tumor growth was confirmed by whole-body fluorescent imaging, and the mice were injected intravenously through the tail vein with 1 × 10 10 DRP of cRGD-modified AAV1eGFP vector, 1 × 10 10 DRP AAV1eGFP vector, or phosphate-buffered saline control. In order to determine the targeting efficiency of cRGD-modified AAV vectors, the mice were killed two weeks after vector administration, and the tumor, liver, spleen, and heart tissues were isolated, frozen, cut, and stained for eGFP expression, using a rabbit anti-GFP antibody (Molecular Probes, Invitrogen) overnight at 4 °C, and donkey anti-rabbit IgG-Alexa-488-conjugated antibody (Molecular Probes, Invitrogen) for 1 hour at room temperature. The number of eGFPpositive cells was determined using stained sections observed under ×400 original magnification fluorescence microscopy. Gene transfer was assessed as the average number of positive (green) cells per field of view in five random frozen sections. The data are presented as mean values ± SD. Statistical analysis was performed using GraphPad Prism software.
